MedWatch

New Novo-studies to identify the link between cardiovascular disease and diabetes

Novo Nordisk aims to register the occurrence of cardiovascular disease among type 2 diabetes patients in a new study with 8000 participants from ten different countries. At the same time, the drug group is enrolling Portuguese patients in a similar, but smaller, trial. Both studies are part of the company's venture into new disease areas.

Foto: Niels Hougaard, Jyllands-Posten

During the years, the connection between diabetes, obesity and the risk of developing cardiovascular disease has become more and more evident.

Diabetes drugs like Novo Nordisk's GLP-1 analogues Victoza and Ozempic have shown a positive impact on the cardiovascular risk in patients with type 2 diabetes, and now the Danish drug group wants to further elicit the link between the two disease areas.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier